IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma

NCT03958383 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: hu14.18-IL2
RADIATION: Radiation Therapy
BIOLOGICAL: Nivolumab
BIOLOGICAL: Ipilimumab

Sponsor

University of Wisconsin, Madison

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]